Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

67.59EUR
11:35am EDT
Change (% chg)

€-0.86 (-1.26%)
Prev Close
€68.45
Open
€68.06
Day's High
€68.17
Day's Low
€67.39
Volume
2,577,779
Avg. Vol
2,476,640
52-wk High
€93.82
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.81
Market Cap(Mil.): €88,234.93
Shares Outstanding(Mil.): 1,289.04
Dividend: 2.93
Yield (%): 4.28

Financials

  SASY.PA Industry Sector
P/E (TTM): 21.55 36.61 36.60
EPS (TTM): 3.18 -- --
ROI: 4.96 14.46 13.91
ROE: 7.50 15.26 14.82

Sanofi gets $43 mln U.S. funding to spur Zika vaccine development

Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum.

1:03pm EDT

BRIEF-U.S BARDA grants $43.2 mln to Sanofi for Zika vaccine

* The United States Biomedical Advanced Research and Development Authority (BARDA) agrees to fund the manufacture of an inactivated Zika vaccine for phase II development by Sanofi and its vaccines global business unit Sanofi Pasteur

11:08am EDT

Sanofi may win U.S. approval of $3 billion eczema drug by March

French drugmaker Sanofi  and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

3:26am EDT

Sanofi may win U.S. approval of $3 bln eczema drug by March

Sept 26 French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.

3:24am EDT

BRIEF-Sanofi and Regeneron accepted for priority review by U.S. FDA

* Sanofi and Regeneron announce dupilumab biologics license application accepted for priority review by U.S. FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

1:08am EDT

BRIEF-Sanofi files suit in U.S. to defend paten rights on Lantus and Lantus Solostar

* Files suit in U.S. To defend paten rights on Lantus and Lantus Solostar

Sep 19 2016

New Mexico AG sues Bristol-Myers, Sanofi over blood thinner

New Mexico Attorney General Hector Balderas has sued Bristol-Myers Squibb Co and Sanofi SA's U.S. arm for overstating the effectiveness of and concealing the risks of their blood thinner Plavix.

Sep 16 2016

UPDATE 2-Teva, Intel to develop wearable tech for Huntington's disease

Sept 15 Teva Pharmaceutical Industries Ltd said on Thursday it was collaborating with Intel Corp to develop a wearable technology platform to track the progression of disease in patients with Huntington's, a fatal degenerative disorder.

Sep 15 2016

Sanofi, Google parent form $500 million diabetes joint venture

PARIS French drugmaker Sanofi and Verily, the life sciences unit of Google parent Alphabet Inc, on Monday said they would invest about $500 million in a joint venture combining devices with services to improve diabetes care, an example of growing ties between the pharma and tech sectors.

Sep 12 2016

UPDATE 2-Sanofi, Google parent form $500 mln diabetes joint venture

PARIS, Sept 12 French drugmaker Sanofi and Verily, the life sciences unit of Google parent Alphabet Inc, on Monday said they would invest about $500 million in a joint venture combining devices with services to improve diabetes care, an example of growing ties between the pharma and tech sectors.

Sep 12 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Finlabo SIM Spa
$10.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.